Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04656262
Other study ID # IOV-2018-STS-METROPHOLYS
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date September 10, 2018
Est. completion date January 31, 2023

Study information

Verified date March 2022
Source Istituto Oncologico Veneto IRCCS
Contact Gian Luca De Salvo
Phone 0039-049-8215710
Email gianluca.desalvo@iov.veneto.it
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To compare the efficacy, as measured by time to treatment failure, of metronomic cyclophosphamide with respect to doxorubicin in elderly patients affected by mSTS.


Description:

This phase III randomized clinical trial was designed to compare metronomic Cyclophosphamide with standard Doxorubicin for the first-line treatment of elderly cancer patients with advanced inoperable or metastatic STS: i) ARM A (experimental): Metronomic Cyclophosphamide ii) ARM B (control): Doxorubicin up to six cycles


Recruitment information / eligibility

Status Recruiting
Enrollment 132
Est. completion date January 31, 2023
Est. primary completion date July 31, 2022
Accepts healthy volunteers No
Gender All
Age group 70 Years and older
Eligibility Inclusion Criteria: Patients may be included in the study only if they meet all the following criteria: 1. Histologically proven diagnosis of soft tissue sarcoma. 2. Advanced unresectable or metastatic soft tissue sarcoma not previously treated with chemotherapy for metastatic disease. 3. At least one measurable lesion according to RECIST1.1 criteria. 4. Availability of a tumor sample (primary and/or metastatic sites). 5. Age = 70 years (70-75 years if UNFIT at G8; >75 independent of G8 score) 6. ECOG PS 0-2. 7. Life expectancy of at least 12 weeks. 8. Neutrophils =1.5 x 109/L, Platelets =100 x 109/L, Hgb = 9 g/dl. 9. Adequate hepatic function, defined as: Total bilirubin = 1.5 time the upper-normal limits (ULN) of the normal values, ASAT (SGOT) and/or ALAT (SGPT) = 2.5 x ULN (or <5 x ULN in case of liver metastases) 10. Alkaline phosphatase = 2.5 x ULN (or <5 x ULN in case of liver metastases). 11. Creatinine clearance = 30 mL/min. 12. Normal cardiac function, with left ventricular ejection fraction (LVEF) =50%. 13. Male subjects with female partners of childbearing potential must be willing to use adequate contraception as approved by the investigator 14. Geriatric assessment by means of G8 screening tool and CRASH score. 15. Will and ability to comply with the protocol. 16. Written informed consent to study participation. Exclusion Criteria: - Patients will be excluded from the study for any of the following reasons: 1. Previous treatment for metastatic disease. 2. Previous (neo) adjuvant chemotherapy with anthracyclines. 3. Radiotherapy to any site within 4 weeks before the study. 4. Untreated brain metastases or spinal cord compression or primary brain tumors. 5. Active uncontrolled infections or other clinically relevant concomitant illness contraindicating chemotherapy administration. 6. Clinically significant (i.e. active) cardiovascular disease for example cerebrovascular accidents (=6 months), myocardial infarction (=6 months), unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure (CHF), serious cardiac arrhythmia requiring medication. 7. Treatment with any investigational drug within 30 days prior to enrollment or 2 investigational agent half-lives (whichever is longer) 8. Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of localized basal and squamous cell carcinoma or cervical cancer in situ. 9. Lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome, or inability to take oral medication. 10. Known hypersensitivity to trial drugs or hypersensitivity to any other component of the trial drugs. 11. Any concomitant drugs contraindicated for use with the trial drugs according to the product information of the pharmaceutical companies. 12. Sexually active males unwilling to practice contraception during the study and until 6 months after the last trial treatment.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Cyclophosphamide
Cyclophosphamide is formulated as coated tablets of 50mg for oral administration
Doxorubicin
Doxorubicin is formulated as 60 mg/mq for infusional use (i.v use)

Locations

Country Name City State
Italy Istituto Ortopedico Rizzoli IRCCS Bologna
Italy Policlinico Sant'Orsola Malpighi Bologna BO
Italy Fondazione del Piemonte per l'Oncologia IRCCS Candiolo
Italy IRST Romagnolo IRCCS Meldola
Italy Istituto Nazionale Tumori IRCCS Milano
Italy Istituto Oncologico Veneto IRCCS Padova
Italy AOU Policlinico Giaccone Palermo Palermo
Italy Ospedale Misericordia e Dolce Prato
Italy IFO - Istituto Regina Elena Roma
Italy Policlinico Universitario Campus Biomedico Roma
Italy Istituto Clinico Humanitas Rozzano MI
Italy Presidio Sanitario Humanitas - Gradenico Torino
Italy AOUI Policlinico Borgo Roma Verona

Sponsors (2)

Lead Sponsor Collaborator
Istituto Oncologico Veneto IRCCS Ministry of Health, Italy

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time to treatment failure Progressive disease is defined as per RECIST 1.1 criteria based on investigator assessment.
Toxicity is assessed according to NCI-CTCAE criteria v. 4.03
From date of randomization until the date of treatment discontinuation due to disease progression, toxicity leading to treatment discontinuation, or death, whichever occurs first, assessed up to 12 months
Secondary Progression free Survival Progressive disease is defined as per RECIST 1.1 criteria based on investigator assessment. From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months
Secondary Overall survival Overall Survival is defined as the time from date of randomization to the date of death due to any cause Time from randomization to the date of death due to any cause or last follow up assessed up to 12 months
Secondary Overall Toxicity Rate Toxicities will be recorded, classified, graded and managed according to NCI CTCAE v. 4.03. From signing IC until 30 days after last study treatment
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04577014 - Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma Phase 1/Phase 2
Recruiting NCT03077178 - Impact of Locoregional Treatment of Soft Tissue Sarcoma on Status of Patients Aged 70 Years and Over N/A
Not yet recruiting NCT06110650 - A Study of Surufatinib in the Treatment of Advanced Soft Tissue Sarcoma N/A
Terminated NCT03735758 - Quality of Life in Patients With Non-adipocyte Soft Tissue Sarcoma Under Palliative Chemotherapy or Pazopanib Phase 4
Not yet recruiting NCT03951571 - Efficacy and Safety of Anlotinib in Adjuvant Therapy for High-grade Soft Tissue Sarcoma Phase 2
Enrolling by invitation NCT03134742 - Radiation Effects on Bone
Not yet recruiting NCT06252727 - Fluorescent Aided Resection and Evaluation of Soft Tissue Sarcomas (FLARES) Phase 1
Recruiting NCT04617327 - Pre-operative RadiothErapy for Soft Tissue SarcOmas N/A
Recruiting NCT06385288 - Blood and Tissue Extraction for Immunological Examinations During Neoadjuvant Therapy of Soft Tissue Sarcomas N/A
Recruiting NCT05116254 - Sarcomas and DDR-Inhibition; a Combined Modality Study Phase 1
Active, not recruiting NCT03526679 - Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma Phase 1/Phase 2
Recruiting NCT04008238 - Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients N/A
Recruiting NCT04095208 - Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study Phase 2
Recruiting NCT04330456 - Combined Treatment of Patients With Soft Tissue Sarcoma Including Preoperative Stereotactic Radiation Therapy and Postoperative Conformal Radiation Therapy N/A
Completed NCT03833037 - Study of a Cohort of Cases of Synovial Sarcoma Treated in the Orthopedic Surgery and Traumatology Department of the Hospital de Sant Pau Between 1983 and 2016
Completed NCT03056599 - Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma Phase 1
Recruiting NCT05961761 - Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients Phase 2
Recruiting NCT06273852 - A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors Early Phase 1
Recruiting NCT05182164 - Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas Phase 2
Withdrawn NCT03104335 - Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial Phase 2